Managing treatment-related adverse events associated with Alk inhibitors
about
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyActivity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Increases in serum CYFRA21-1 concentration during successful treatment with crizotinib.Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.Management of pulmonary toxicity associated with targeted anticancer therapies.Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer.Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement.Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors.Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling.Crizotinib-induced toxicity in an experimental rat model.Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs.ALK inhibitors, resistance development, clinical trials.
P2860
Q26795555-0FB4C73B-D287-4F1D-92A5-E8B887DA3E03Q27853360-3E9EECE9-984A-4541-BD33-05E2B752B9A0Q34496562-9619EFA3-22EC-4D26-B419-5DA9B4A1D80DQ38551764-F257A292-0CA7-40F0-8D2E-655C16417A8EQ38570532-76399FF0-683A-4FD7-AB8A-8E3F5EEB8D2EQ38792120-E3CFF971-AD3A-41BF-9E81-1A7AE740354CQ38930084-A1D13810-E3D8-4D75-B532-3BEFFFD039CEQ40180955-5D17CCAA-9DD6-4752-9481-D0BFBC6CB8B1Q41341776-386C6DA4-FC8A-4298-AA40-43EF263AEF49Q50130090-D2770E8F-4AF3-42B1-8F3C-CA298AF6115EQ53148505-29496382-5029-47D4-85DF-D31AB4868A43Q54123036-A95C17D2-5AF0-4C61-8B80-1BF2AEFB3840Q55059446-6F6FC3BF-3301-45A2-B80C-3B6E90623186Q55262467-C5BEE148-04AA-449B-9249-9F4DA42DED8F
P2860
Managing treatment-related adverse events associated with Alk inhibitors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Managing treatment-related adverse events associated with Alk inhibitors
@en
Managing treatment-related adverse events associated with Alk inhibitors.
@nl
type
label
Managing treatment-related adverse events associated with Alk inhibitors
@en
Managing treatment-related adverse events associated with Alk inhibitors.
@nl
prefLabel
Managing treatment-related adverse events associated with Alk inhibitors
@en
Managing treatment-related adverse events associated with Alk inhibitors.
@nl
P2860
P356
P1433
P1476
Managing treatment-related adverse events associated with Alk inhibitors
@en
P2093
J M Rothenstein
P2860
P356
10.3747/CO.21.1740
P577
2014-02-01T00:00:00Z